| 1 |
Khattri RB, Batra A, Matheny M, Hart C, Henley-Beasley SC, Hammers D, Zeng H, White Z, Ryan TE, Barton E, Bernatchez P, Walter GA. Magnetic resonance quantification of skeletal muscle lipid infiltration in a humanized mouse model of Duchenne muscular dystrophy. NMR Biomed 2023;36:e4869. [PMID: 36331178 DOI: 10.1002/nbm.4869] [Reference Citation Analysis]
|
| 2 |
White Z, Sun Z, Sauge E, Cox D, Donen G, Pechkovsky D, Straub V, Francis GA, Bernatchez P. Limb-girdle muscular dystrophy type 2B causes HDL-C abnormalities in patients and statin-resistant muscle wasting in dysferlin-deficient mice. Skelet Muscle 2022;12:25. [PMID: 36447272 DOI: 10.1186/s13395-022-00308-6] [Reference Citation Analysis]
|
| 3 |
Vu Hong A, Bourg N, Sanatine P, Poupiot J, Charton K, Gicquel E, Massourides E, Spinazzi M, Richard I, Israeli D. Dlk1-Dio3 cluster miRNAs regulate mitochondrial functions in the dystrophic muscle in Duchenne muscular dystrophy. Life Sci Alliance 2023;6. [PMID: 36265896 DOI: 10.26508/lsa.202201506] [Reference Citation Analysis]
|
| 4 |
Almeida-Becerril T, Rodríguez-Cruz M, Hernández-Cruz SY, Ruiz-Cruz ED, Mendoza CRS, Cárdenas-Conejo A, Escobar-Cedillo RE, Ávila-Moreno F, Aquino-Jarquin G. Natural history of circulating miRNAs in Duchenne disease: Association with muscle injury and metabolic parameters. Acta Neurol Scand 2022. [PMID: 36000352 DOI: 10.1111/ane.13673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Israeli D, Vu Hong A, Corre G, Miagoux Q, Richard I. Deciphering the Molecular Mechanism of Incurable Muscle Disease by a Novel Method for the Interpretation of miRNA Dysregulation. ncRNA 2022;8:48. [DOI: 10.3390/ncrna8040048] [Reference Citation Analysis]
|
| 6 |
Podkalicka P, Mucha O, Kaziród K, Szade K, Stępniewski J, Ivanishchuk L, Hirao H, Pośpiech E, Józkowicz A, Kupiec-Weglinski JW, Dulak J, Łoboda A. miR-378 affects metabolic disturbances in the mdx model of Duchenne muscular dystrophy. Sci Rep 2022;12:3945. [PMID: 35273230 DOI: 10.1038/s41598-022-07868-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Coles CA, Woodcock I, Pellicci DG, Houweling PJ. A Spotlight on T Lymphocytes in Duchenne Muscular Dystrophy—Not Just a Muscle Defect. Biomedicines 2022;10:535. [DOI: 10.3390/biomedicines10030535] [Reference Citation Analysis]
|
| 8 |
Bourg N, Vu Hong A, Lostal W, Jaber A, Guerchet N, Tanniou G, Bordier F, Bertil-Froidevaux E, Georger C, Daniele N, Richard I, Israeli D. Co-Administration of Simvastatin Does Not Potentiate the Benefit of Gene Therapy in the mdx Mouse Model for Duchenne Muscular Dystrophy. Int J Mol Sci 2022;23:2016. [PMID: 35216132 DOI: 10.3390/ijms23042016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Vu Hong A, Bourg N, Sanatine P, Poupiot J, Charton K, Gicquel E, Massourides E, Spinazzi M, Richard I, Israeli D. Dlk1-Dio3 cluster miRNAs regulate mitochondrial functions in Duchenne muscular dystrophy.. [DOI: 10.1101/2021.10.20.464950] [Reference Citation Analysis]
|
| 10 |
Ohlendieck K, Swandulla D. Complexity of skeletal muscle degeneration: multi-systems pathophysiology and organ crosstalk in dystrophinopathy. Pflugers Arch 2021;473:1813-39. [PMID: 34553265 DOI: 10.1007/s00424-021-02623-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 11 |
Whitehead NP, Kim MJ, Bible KL, Adams ME, Froehner SC. Rebuttal to: Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy, Verhaart et al. 2020. J Neuromuscul Dis 2021;8:865-6. [PMID: 34542082 DOI: 10.3233/JND-219005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Vu Hong A, Sanson M, Richard I, Israeli D. A revised model for mitochondrial dysfunction in Duchenne muscular dystrophy. Eur J Transl Myol 2021;31. [PMID: 34533019 DOI: 10.4081/ejtm.2021.10012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 13 |
Mucha O, Podkalicka P, Kaziród K, Samborowska E, Dulak J, Łoboda A. Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy. Skelet Muscle 2021;11:21. [PMID: 34479633 DOI: 10.1186/s13395-021-00276-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 14 |
Amor F, Vu Hong A, Corre G, Sanson M, Suel L, Blaie S, Servais L, Voit T, Richard I, Israeli D. Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle 2021;12:677-93. [PMID: 34037326 DOI: 10.1002/jcsm.12708] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
|
